DYLOJECT Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Dyloject, and what generic alternatives are available?

Dyloject is a drug marketed by Javelin Pharms Inc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-four patent family members in eleven countries.

The generic ingredient in DYLOJECT is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dyloject

A generic version of DYLOJECT was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26^th, 1996.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DYLOJECT?
What are the global sales for DYLOJECT?
What is Average Wholesale Price for DYLOJECT?

Summary for DYLOJECT

International Patents:	24
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	121
Patent Applications:	4,203
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DYLOJECT
DailyMed Link:	DYLOJECT at DailyMed

Drug patent expirations by year for DYLOJECT

Paragraph IV (Patent) Challenges for DYLOJECT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
DYLOJECT	Injection	diclofenac sodium	37.5 mg/mL, 1 mL single-dose vials	022396	1	2015-12-15

US Patents and Regulatory Information for DYLOJECT

DYLOJECT is protected by one US patents.

Patents protecting DYLOJECT

Formulations of low dose diclofenac and beta-cyclodextrin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: MANAGEMENT OF PAIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Javelin Pharms Inc	DYLOJECT	diclofenac sodium	SOLUTION;INTRAVENOUS	022396-001	Dec 23, 2014		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DYLOJECT

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Javelin Pharms Inc	DYLOJECT	diclofenac sodium	SOLUTION;INTRAVENOUS	022396-001	Dec 23, 2014	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DYLOJECT

See the table below for patents covering DYLOJECT around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Japan	2014005309	FORMULATION OF LOW DOSE DICLOFENAC AND &bgr;-CYCLODEXTRIN	⤷ Sign Up
Japan	5823093		⤷ Sign Up
South Korea	20170123724	저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형 (- FORMULATIONS OF LOW DOSE DICLOFENAC AND BETA-CYCLODEXTRIN)	⤷ Sign Up
European Patent Office	2522343	Formulations de faible dose du diclofénac et de beta-cyclodextrine (Formulations of Low Dose Diclofenac and Beta-Cyclodextrin)	⤷ Sign Up
Israel	194185	פורמולציות של דיקלופנאק במינון נמוך וציקלודקסטרין ושימוש בהן לשיכוך כאבים (Formuations of low dose diclofenac and beta-cyclodextrin and use thereof for effecting analgesia)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for DYLOJECT

Paragraph IV (Patent) Challenges for DYLOJECT

Patents protecting DYLOJECT

Make Better Decisions: Try a trial or see plans & pricing